Shire Late-Stage Pipeline Is Focused On ADHD Market
Executive Summary
Three of the four new drug applications that Shire plans to file with FDA this year are treatments for attention deficit/hyperactivity disorder
You may also be interested in...
Shire Adds Two Pipeline Products With TKT Acquisition
Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate
Shire Adderall XR Sales Suspended In Canada; FDA Stands By “Black Box”
Differences between FDA and Health Canada's regulatory responses to adverse event reports for Adderall XR are likely to raise more questions about FDA's drug safety review process
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011